Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2766751 | 0.91 | AR (0.63) | ARMEN1MAPTRAB9AKMT2A | |
| SCHEMBL5685907 | 0.91 | AR (0.63) | ARMEN1MAPTRAB9AKMT2A | |
| SCHEMBL12591156 | 0.89 | AR (0.65) | AR | |
| SCHEMBL2769146 | 0.89 | AR (0.65) | AR | |
| SCHEMBL18671312 | 0.89 | AR (0.64) | AR | |
| SCHEMBL2767185 | 0.89 | AR (0.64) | AR | |
| SCHEMBL5682122 | 0.89 | AR (0.64) | ARKMT2A | |
| SCHEMBL2767389 | 0.89 | AR (0.64) | ARKMT2A | |
| SCHEMBL2767055 | 0.88 | AR (0.59) | ARMEN1MAPTRAB9AKMT2A | |
| SCHEMBL12706728 | 0.88 | AR (0.63) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641745-B1 | PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | ORION CORP (FI) | 2010-04-14 | — | — | EP | disclosed |
| US-7390923-B2 | Propionamide derivatives useful as androgen receptor modulators | ORION CORPORATION (FI) | 2008-06-24 | — | — | US | disclosed |
| US-20070123512-A1 | Propionamide derivatives useful as androgen receptor modulators | ORION CORPORATION (FI) | 2007-05-31 | — | — | US | disclosed |
| EP-1641745-A1 | PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | Orion Corporation (FI) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005000794-A1 | PROPIONAMIDE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS | ORION CORPORATION (FI) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123512-A1 | Propionamide derivatives useful as androgen receptor modulators | NR5A1, FSHR, GNRHR | AR 4/4885MEN1 2612/4885MAPT 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.